This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.

A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.

Insights from clinicians on the practical use of LIVTENCITY in post-transplant CMV, including case reflections and real-world treatment considerations.

An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.